The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses
Eui‐Cheol Shin(Korea Advanced Institute of Science and Technology), Sung Key Jang(Pohang University of Science and Technology), Takaji Wakita(National Institute of Infectious Diseases), Marc P. Windisch(Institut Pasteur Korea), Pil Soo Sung(Catholic University of Korea), Wonseok Kang(Samsung Medical Center), Kwang‐Hyub Han(Yonsei University), Seungtaek Kim(Institut Pasteur Korea), Jin Zhong(Chinese Academy of Sciences), Koichi Watashi(Tokyo University of Science), Seong‐Jun Kim(University Health Network), Su‐Hyung Park(Korea Advanced Institute of Science and Technology), Jun Yong Park(Yonsei University), Takanobu Kato(National Institute of Infectious Diseases), Jong‐Won Oh(Yonsei University), Ji Won Han(The Catholic University of Korea Seoul St. Mary's Hospital)
Cited by 7
Related Papers
The lipid droplet is an important organelle for hepatitis C virus production
|Nature Cell Biology|2007|1.2k
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)
|Journal of Microbiology and Biotechnology|2020|1k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Tissue Adhesive Catechol‐Modified Hyaluronic Acid Hydrogel for Effective, Minimally Invasive Cell Therapy
|Advanced Functional Materials|2015|428